ScienceBowel cancer trial reportedly records no relapses after 33 months of follow-up
A post describing the UK-led NEOPRISM-CRC trial says patients with stage 2 or 3 mismatch repair-deficient bowel cancer received nine weeks of pembrolizumab immunotherapy before surgery.
TLDR
A post describing updated NEOPRISM-CRC results says all treated patients remained relapse-free after 33 months of follow-up. The trial involved nine weeks of pembrolizumab before surgery for patients with stage 2 or 3 mismatch repair-deficient (dMMR) bowel cancer. The post also says researchers developed personalized blood tests to track tumor DNA and predict who would benefit most from treatment.
Combined views
3.2K
1 Source, first seen 10d ago
Bowel cancer trial reportedly records no relapses after 33 months of follow-up
A post describing the UK-led NEOPRISM-CRC trial says patients with stage 2 or 3 mismatch repair-deficient bowel cancer received nine weeks of pembrolizumab immunotherapy before surgery.